We compared results obtained from two parathyrin (parathyroid hormone) assays with differing specificities, using sera from 172 normal donors and from 98 patients with disorders of calcium regulation. Intact parathyrin was measured in both assays; the C-parathyrin assay also measured the 53-84 amino acid C-terminal hormone fragment; the N-parathyrin assay also measured the 1-34 N-terminal fragment. The reference interval for the Cparathyrin assay 
Diagnostic Utility of C-Terminal Parathyrin Measurement as Compared with Measurements of N-Terminal Parathyrin and Calcium in Serum

Marcia Simon and Jose Cuan
We compared results obtained from two parathyrin (parathyroid hormone) assays with differing specificities, using sera from 172 normal donors and from 98 patients with disorders of calcium regulation. Intact parathyrin was measured in both assays; the C-parathyrin assay also measured the 53-84 amino acid C-terminal hormone fragment; the N-parathyrin assay also measured the 1-34 N-terminal fragment. The reference interval for the Cparathyrin assay ( (1) . This hormone is present in serum in at least three forms (2) : (a) intact hormone (84 amino acids), (b) hormone fragments that include the carboxy-terminal amino acid sequence (C-PTH), and (c) a fragment including the first 34 amino acids from the amino terminus (N-PTH).
Antibodies to PTH differ in their relative reactivity toward these several species. Some investigators have proposed that the diagnostic utility of PTH assays can be specifically related to cross-reactivity studies with the active and inactive fragments (3). The present study was undertaken to determine the relationship between assay results obtained with an antibody reacting primarily with N-PTH (and intact hormone) and another antibody reacting primarily with C-PTH (and intact hormone). These assays are more completely described in an accompanying paper (4) and in a previous report (5 
Selection of Patients and Donors
We assayed sera from 111 well adults to establish a reference interval in the C-PTH assay and sera from 61 well adults for the N-PTH reference interval. 
Results
We separated sera from 21 healthy adults into two aliquots and analyzed them, using each PTH antibody. As shown in Figure 1 , results from the C-PTH assay were up to fivefold higher than N-PTH results. However, there was no consistent relation between C-PTH and N-PTH results (both assays also measure the intact hormone), so a factor could not be used to We saw no correlation between results for serum calcium and C-PTH in the normal or primary hyperparathryoid groups. Serum from 17 patients with chronic renal failure was an-SAMPLE ID NUMBER (Figure 4 ) are above the reference intervals for both PTH assays. As with other samples analyzed, PTH results were generally higher in the C-assay than the N-assay, but not by a constant factor.
Two patients
with results that were normal by the N-PTH assay had above-normal C-PTH results. C-PTH results from the same patients are plotted vs serum calcium in Figure 5 , which also shows the lower PTH values for patients after successful renal transplantation. (13) . As shown in Figure 2 , the range of values we found from resampling these normal donors is apparently narrower than the range observed by Almquist et al.
(13) in resampling 26 patients with suspected hyperparathyroidism. Perhaps there is a tendency toward more erratic PTH production in patients whose calcium regulation is disturbed.
We saw no negative correlation between serum calcium and C-PTH in the normal donors, in contrast to reports with other C-PTH antibodies (10) . If, as has been suggested (14) , one of the mechanisms for feedback control of PTH activity by increasing serum calcium is increased cleavage of active intact hormone to inactive C-fragments and small inactive N-fragments within the gland, a negative correlation would not be expected. Also in contrast to other reports (10), we did not see a positive correlation between serum calcium and C-PTH in our patients with primary hyperparathyroidism. Although some of the C-PTH results in the hyperparathyroid patients overlapped the normal range, these patients could be distin- 
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tion were examined for N-PTH, C-PTH, and calcium; results are shown in Table 2 . The pseudohypoparathyroid patient showed serum calcium concentrations at the low limit of the normal range, and increased C-PTH. Two of the three osteomalacia patients had increased PTH values, and the two patients whose serum calcium was measured had results that were within the reference interval. In the two thyrotoxicosis patients, calcium was increased and C-PTH and one N-PTH were below the reference interval; the other N-PTH value was within it.
Discussion
Several investigators have sought to correlate the results from PTH antibody-specificity studies with clinical utility, in an effort to use N-PTH or C-PTH cross reactivity to predict the ability of an antibody to discriminate among clinically distinct classes of patients (3, 7). More recently, several investigators have suggested that such a view may be an overgeneralization (1, 8) . In the present study, we examined sera from 172 normal donors and 92 patients with disorders of calcium regulation, using two PTH antibodies that have been characterized as cross reacting primarily with the C-terminal region (4) or with the N-terminal region (5) of the molecule. The intact hormone contains both regions; thus, each antibody reacts to the intact hormone in addition to selected fragments, according to its specificity. Parallel standard curves were found with intact human PTH in both assays (4). Because both the intact hormone and the N-terminal fragment are thought to be physiologically active (9) , the N-PTH assay in this report could perhaps more properly be designated an assay of "active" PTH.
The strategy of using discrimination among clinical groups to characterize an assay deserves some discussion. If only patients who meet very rigorous diagnostic criteria are included in the study, the assay will appear to discriminate better than if patients with early or mild disease (more typical of those seen in routine clinical practice) are included. Thus, the characteristics of the normal populations (i.e., age, health, sex) and hyperparathyroid patients (duration of disease, size and number of diseased glands) may be more influential than is antibody specificity. This point is illustrated by studies involving a particular C-PTH antibody and two identically defined patient populations. One investigator found only 10% overlap with normal values of values for primary hyperparathyroid patients (10); another found 40% overlap (11) and also found some results from hyperparathyroid patients to be as low as from hypoparathyroid patients-results clearly at variance with the earlier (10) study. The most likely explanation for this discrepancy is that the patient groups, although identically defined, differed in the two studies. These limitations in experimental design also influence the clinical data presented in this report.
In patients with chronic renal failure, serum C-PTH as well as N-PTH usually exceeded the reference interval.
Many of these patients have a low serum calcium concentration as a result of their primary renal disease (15) . PTH secretion is stimulated by chronic hypocalcemia and hyperphosphatemia; the high resulting parathyroid activity may contribute to the toxic symptoms of uremia (16) and may interfere with the success of subsequent renal transplantation (15) . Another complication of long-standing renal failure is that chronically stimulated hyperplastic parathyroid glands may become autonomous and continue to secrete large amounts of PTH after the hypocalcemia has been corrected. Monitoring the serum PTH is therefore recommended in the management of chronic renal failure (15) .
Results from C-PTH specific assays generally are much higher in these patients than N-PTH results because the normal clearance of C-PTH by the kidney is severely compromised by disease (17) . Therefore, patients with increased C-PTH but normal N-PTH values may not be subject to the deleterious effects of high hormone concentrations, because the C-fragments are inactive by-products of secretion. Criteria for the use of one assay or the other remain to be established in clinical studies. From the results in Figure 4 it would seem that the two assays may be used concurrently but not interchangeably during the course of treatment.
PTH assay is frequently used in the differential diagnosis of the etiology of hypercalcemia (18) . As a result of the increasing use of multi-test panels in routine health screening, the incidence of hypercalcemia detected has risen to 1% in the general population (19) . Of these, 25% are found to have primary hyperparathyroidism and about 50% have malignancies (20) . In the present study, all patients with hypercalcemia malignancy tested showed N-PTH and C-PTH results within or below the reference interval. It has been proposed that the term "ectopic hyperparathyroidism" be used to describe a syndrome in malignancy patients who have hypercalcemia and above-normal PTH results in the absence of hyperplastic or adenomatous parathyroid glands (3, 7) . Such non-parathyroid production of PTH was not found in the present series and may be related to cross-reacting substances detected by some other radioimmunoassays (20) (20, 21) . The degree of such overlap in the present study ( Figure 6 ) was not markedly different in the two PTH assays. The more rapid N-PTH assay may be appropriate in the differential diagnosis of life-threatening hypercalcemic crisis such as may occur with hemorrhaging parathyroid adenomas (22) or in non-parathyroid malignancies (20) .
The most common treatment of primary hyperparathyroidism is parathyroidectomy (23) . The surgery is difficult to perform and can result in inadvertent removal of too much tissue, causing persistent hypoparathyroidism in approximately 15% of cases (24, 25) . Because the three to six parathyroid glands may be dispersed throughout the neck and mediastinum, some residual PTH production may remain even after surgery (23) . Some measurable PTH was found in the hypoparathyroid patients listed in Table 1 , but because half were below the normal range and all were relatively low, the results found were appropriate for hypoparathyroidism. In general, C-PTH results were higher in all categories than N-PTH results. No consistent relationship was found between the results from two assays within any diagnosed group, and the assays probably should not be used interchangeably in any given patient.
The ability of the two assays to distinguish among clinical groups was found to be fairly similar in spite of markedly different antibody specificities.
